U.S. Water Utilities Stock News

If you are wondering whether Hawkins at around US$152 is still attractively priced after a strong multi year run, this breakdown is designed to help you size up the current valuation with clear, practical checks. The share price has seen a 6.6% gain over the last 30 days, a 4.6% return year to date, and a 33.7% return over the past year, while the 3 year return is very large at close to 3x. These moves have drawn more attention to how the market is treating specialty chemical suppliers like...

Teradyne (TER) has drawn attention after recent trading, with the stock last closing at $228.15. For investors, the focus is on how this price compares with the company’s fundamentals. See our latest analysis for Teradyne. The recent share price move to $228.15 sits within a strong run, with a 30-day share price return of 23.18% and a 1-year total shareholder return of 65.56% suggesting momentum has been building rather than fading. If Teradyne’s jump has you thinking about where else growth...

Marriott International recently outlined leadership changes and global growth efforts, including senior executive retirements, new regional presidents, and hotel expansion in Saudi Arabia through its agreement with Al Qimmah Hospitality. These moves, alongside fresh brand partnerships and elevated experiential offerings at properties like The Ritz-Carlton, Amelia Island, highlight how Marriott is seeking to extend its reach across both luxury and midscale travel segments. Next, we’ll examine...

If you have ever wondered whether Tesla's share price still lines up with the underlying business, you are not alone. This article is written with that exact question in mind. Tesla's shares most recently closed at US$437.50, with a 1.7% decline over the last 7 days, a 9.5% decline over 30 days, a 0.1% decline year to date, a 2.6% gain over 1 year and a very large 3 year return, alongside a 55.0% return over 5 years. Recent news coverage has centered on Tesla's position in the electric...

If you are wondering whether Moody's current share price lines up with its underlying value, you are not alone. Many investors are asking the same question right now. The stock last closed at US$538.92, with stated returns of 1.4% over 7 days, 8.0% over 30 days and year to date, 14.1% over 1 year, 72.4% over 3 years and 110.7% over 5 years. Recent coverage has focused on how Moody's position as a major credit rating and analytics provider feeds into market sentiment on credit conditions and...

Copa Holdings, S.A. has already reported its December 2025 preliminary traffic results, showing capacity of 2,932.4 million available seat miles, revenue passenger miles of 2,521.0 million, and an 86.0% load factor, all higher than a year earlier. The simultaneous rise in capacity and traffic, with a slightly higher load factor, points to efficient use of additional seats and firm underlying demand across Copa’s network. We’ll now examine how December’s higher load factor and traffic growth...

Fastenal (FAST) is back in focus after its board declared a cash dividend of $0.24 per share, as investors watch for the company’s January 20 quarterly earnings update and any fresh read on industrial demand. See our latest analysis for Fastenal. Fastenal’s recent cash dividend news and the upcoming January 20 update come as the share price sits at $43.74, with an 8.16% year to date share price return and a 17.43% 1 year total shareholder return, following a multi year total shareholder...

Black Hills Corp. has completed and energized its 260-mile, US$350 million Ready Wyoming electric transmission expansion, which was placed into service on schedule in December 2025 and now links its South Dakota and Wyoming electric systems. The project’s cost recovery structure, about US$300 million through the Wyoming Transmission Rider and roughly US$50 million via future base rates, highlights how Black Hills is using regulatory mechanisms to support grid resiliency and long-term cost...

If you are wondering whether Pure Storage's current share price lines up with its underlying worth, this article is here to walk you through what the numbers actually say about value. The stock last closed at US$72.90, with returns of 8.8% over the past 7 days, 9.9% over 30 days, 5.6% year to date, 10.0% over 1 year, 180.3% over 3 years and 217.2% over 5 years. These figures can change how investors think about both potential and risk. Recent coverage has focused on Pure Storage as a key...

If you are wondering whether Corning is priced attractively after its recent run, this article will walk through what the current share price could imply about its value. At a last close of US$94.20, Corning's shareholders have seen returns of 10.5% over 7 days, 10.3% over 30 days, 3.9% year to date, 92.6% over 1 year, 185.6% over 3 years and 187.5% over 5 years. Recent attention on Corning has centered on ongoing developments in its core glass and materials businesses and how these feed...

If you are wondering whether Klarna Group is attractively priced right now, it helps to step back and look at how its current share price lines up with different valuation checks. The stock last closed at US$29.00, with a 7 day return of a 7.8% decline, a 30 day return of a 1.5% decline, and a 1.5% gain year to date, which may have caught the eye of investors thinking about shifting risk and return. Recent news around Klarna Group has focused on its position in the buy now, pay later space...

On January 14, 2026, Sana Biotechnology presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting 12‑month survival and function of its hypoimmune-engineered islet cell therapy UP421 in a type 1 diabetes patient without immunosuppression and no therapy-related adverse events. The company also outlined 2026 goals for bringing its stem cell-derived islet therapy SC451 into Phase 1 trials and progressing its in vivo CD19-directed CAR T program SG293, underscoring efforts to...

Avista (AVA) has put a four year general rate case in front of Washington state regulators, a move that could influence how the utility recovers rising costs and funds grid, wildfire, and clean energy investments. See our latest analysis for Avista. Against the backdrop of this multi year rate case, Avista’s share price has been relatively firm, with a 90 day share price return of 4.53% and a 1 year total shareholder return of 13.59%. This suggests steady rather than surging momentum. If this...

AppFolio (APPF) is back on investor radars after the company reshaped its board and appointed experienced finance executive Saori Casey, while also lining up its next earnings release for late January. See our latest analysis for AppFolio. Those board changes and the upcoming January 29 earnings update come as AppFolio’s US$219.67 share price shows mixed momentum, with a 3.16% 1 day share price return but a 30 day share price decline of 4.93%. Its 3 year total shareholder return of 92.81%...

In recent days, analysts have reiterated their broadly positive stance on Monster Beverage, highlighting its leading position in energy drinks and its long-term distribution and manufacturing partnership with Coca-Cola, which also holds a 19.5% ownership stake. What stands out is Monster’s combination of strong free cash flow generation, disciplined cost control, and high returns on capital, which together point to a business that has become less capital intensive while still investing...

Event context and recent price performance With no single headline event driving attention to Oceaneering International (OII) today, investors may be looking at the stock’s recent returns and fundamentals to understand what the current pricing might reflect. See our latest analysis for Oceaneering International. With the share price at US$27.27, Oceaneering International has seen short term momentum, with a 30 day share price return of 13.34% and a 90 day share price return of 18.00%. The 3...

Earlier this month, the World Orphan Drug Alliance and Syndax Pharmaceuticals announced a collaboration to expand global access to Syndax’s first-in-class menin inhibitor, Revuforj (revumenib), via a Managed Access Program for eligible acute leukemia patients outside the U.S. This move meaningfully broadens potential real-world use of Revuforj in hard-to-treat blood cancers, complementing its existing FDA approvals in specific relapsed or refractory KMT2A-translocated and NPM1-mutated...

Earlier this month, the UK Competition and Markets Authority ordered Aramark to unwind its majority acquisition of offshore caterer Entier due to competition concerns, forcing the company to sell the business it had combined with its existing UK operations. This intervention highlights how regulatory scrutiny can reshape Aramark’s expansion efforts, particularly in specialized markets where consolidation risks reducing customer choice. We’ll now examine how being compelled to divest Entier...

If you are wondering whether Okta's current share price lines up with its underlying worth, this article will help you unpack what the market might be pricing in today. Okta's share price closed at US$89.55, with returns of 2.6% over the last year, 7.1% year to date, a 30.3% gain over three years, and a 66.1% decline over five years, so the stock has treated different time frames very differently. Recent headlines around Okta have focused on its role in identity and access management and how...

What HF Sinclair’s Recent Share Moves Signal for Investors HF Sinclair (DINO) has seen mixed share performance recently, with a 2.5% gain over the past month and a 6.2% decline over the past 3 months. This has put fresh attention on its current valuation. See our latest analysis for HF Sinclair. At a share price of US$48.63, HF Sinclair’s short term share price pressure, including a 1 day decline of 2.4% and a 7 day decline of 3.3%, contrasts with its 1 year total shareholder return of 40.6%...

On December 31, 2025, Range Resources Corporation announced it would fully redeem its US$600,000,000 8.25% senior notes due 2029 on January 15, 2026, at 101.375% of par plus accrued interest, funded via its existing revolving credit facility. This move retires high-coupon debt while shifting funding to shorter-term bank borrowing, putting the company’s balance sheet choices under closer investor and analyst scrutiny. Next, we’ll examine how funding this bond redemption through the revolving...

Earlier this week, Edgewise Therapeutics used its presentation at the 44th J.P. Morgan Healthcare Conference to outline 2026 milestones, including pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy, Phase 2 readouts for EDG-7500 in hypertrophic cardiomyopathy, and continued development of its early-stage heart failure candidate EDG-15400. A distinctive aspect of the update is Edgewise’s attempt to build an integrated neuromuscular and cardiovascular franchise, with...

In recent months, World Kinect Corporation received a consensus “Reduce” rating from six analysts, reported a quarterly update with revenue slightly ahead of expectations but earnings per share below consensus and a 10.5% year-on-year revenue decline, and confirmed a quarterly dividend implying an annualized yield of 2.9% payable on January 16. This mix of cautious analyst sentiment, weaker earnings, and an ongoing dividend payout highlights a tension between income appeal and concerns about...

Recent analyst reports on Marex Group (MRX) highlight increased optimism around the company’s earnings outlook. Several firms have revised their forecasts higher and reiterated positive ratings, drawing fresh attention to the stock. See our latest analysis for Marex Group. The recent earnings optimism has coincided with a 32.28% 90 day share price return and a 21.80% total shareholder return over the past year, suggesting momentum has been building around Marex Group, which had a last close...